Gemcitabine Intravesical System (Inlexzo)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.753 alerts
Get alerted when Policy CP.PHAR.753 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Inlexzo in adult members with BCG-unresponsive non-muscle invasive bladder cancer and other requested indications. It applies to Commercial, HIM/ICHRA, and Medicaid lines of business.
The 2026 annual review added coverage criteria for NMIBC with Ta or T1 papillary tumors in accordance with NCCN recommendations.
HCPCS code J9183 was added for gemcitabine intravesical system, 225 mg.
HCPCS codes J3590 and C9399 were removed from the coding references.
The annual review added the ICHRA line of business.
The policy added an option for use in non-muscle-invasive bladder cancer with Ta or T1 papillary tumors consistent with NCCN guidance.
References were reviewed and updated during the annual policy review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.